These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15715968)

  • 21. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.
    Patel NS; Mathura VS; Bachmeier C; Beaulieu-Abdelahad D; Laporte V; Weeks O; Mullan M; Paris D
    J Neurochem; 2010 Jan; 112(1):66-76. PubMed ID: 19818105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
    Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biphasic effect of PTK7 on KDR activity in endothelial cells and angiogenesis.
    Shin WS; Na HW; Lee ST
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2251-60. PubMed ID: 25986862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.
    Solowiej J; Chen JH; Zou HY; Grant SK; Murray BW
    ACS Chem Biol; 2013 May; 8(5):978-86. PubMed ID: 23441851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity.
    Ottino P; Finley J; Rojo E; Ottlecz A; Lambrou GN; Bazan HE; Bazan NG
    Mol Vis; 2004 May; 10():341-50. PubMed ID: 15162095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF.
    Dardik R; Inbal A
    Exp Cell Res; 2006 Oct; 312(16):2973-82. PubMed ID: 16914140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and function identification of extracellular domain 3 of human vascular endothelial growth factor receptor KDR].
    Zhang J; Zhang Y; Li H; Chen W; Zhang T; Wang M
    Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1962-7. PubMed ID: 19256346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
    Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
    Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
    Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
    Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole.
    Faehling M; Kroll J; Föhr KJ; Fellbrich G; Mayr U; Trischler G; Waltenberger J
    FASEB J; 2002 Nov; 16(13):1805-7. PubMed ID: 12354692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
    Kim SJ; Seo JH; Lee YJ; Yoon JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Oncology; 2005; 68(2-3):204-11. PubMed ID: 16015035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.
    Arao T; Matsumoto K; Furuta K; Kudo K; Kaneda H; Nagai T; Sakai K; Fujita Y; Tamura D; Aomatsu K; Koizumi F; Nishio K
    Anticancer Res; 2011 Sep; 31(9):2787-96. PubMed ID: 21868521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.